billHR6219Event Thursday, November 20, 2025Analyzed

Conscience Protections for Medical Residents Act

Neutral
Impact2/10

Summary

The Conscience Protections for Medical Residents Act (HR6219) was introduced in the House on November 20, 2025, and referred to two committees. This early-stage bill focuses on medical resident training protections and does not appropriate funds or directly alter market dynamics for publicly traded companies. Its current status indicates no immediate financial impact on the healthcare sector.

Key Takeaways

  • 1.HR6219 is an early-stage procedural bill introduced in the House on November 20, 2025.
  • 2.The bill does not appropriate or authorize any funds, indicating no direct financial impact on markets.
  • 3.Its focus on medical resident training protections has no immediate financial implications for publicly traded healthcare companies.
  • 4.The presence of a companion bill (S3238) suggests coordinated legislative interest but does not accelerate its early-stage status.

Market Implications

The Conscience Protections for Medical Residents Act (HR6219) is currently in the committee referral stage, having been introduced in November 2025. This bill does not contain any provisions for funding or direct market regulation that would affect the financial performance of publicly traded companies in the Healthcare sector. Its focus is on specific training requirements within medical residency programs, which are not direct drivers of corporate revenue or profitability for large healthcare providers or insurers. Therefore, there are no immediate market implications or specific tickers to highlight based on this legislative action.

Full Analysis

The Conscience Protections for Medical Residents Act (HR6219) was introduced in the House of Representatives on November 20, 2025, by Rep. Murphy (R-NC-3) and 25 cosponsors. The bill has been referred to the Committee on Ways and Means and the Committee on Energy and Commerce. This is an early procedural stage for the legislation, with no further action recorded since its introduction. The bill aims to amend title XVIII of the Social Security Act to prohibit approved medical residency training programs under the Medicare program from requiring opt-out abortion training. Specifically, it would prevent programs from providing or requiring such training without a participant voluntarily opting in, or from discriminating against participants who do not opt-in or perform such procedures. The bill does not authorize or appropriate any funds. Therefore, there is no direct money trail or financial mechanism that would immediately impact publicly traded companies. Given the bill's early stage and its focus on training program requirements rather than direct funding or broad regulatory changes affecting healthcare corporations' revenue streams, there are no immediate structural winners or losers among publicly traded companies. The bill's provisions relate to the internal operations and training protocols of medical residency programs, which are not typically direct drivers of market performance for large healthcare entities. There is an identical companion bill, S3238, introduced in the Senate, which indicates coordinated legislative effort but does not change the bill's early procedural status. To progress, HR6219 would need to be considered and passed by its assigned committees, then by the full House, and subsequently by the Senate, before potentially being signed into law. This process typically takes a significant amount of time, and many bills introduced at this stage do not advance further. As of today, 2026-04-07, the bill remains in the committee referral stage.

Market Impact Score

2/10
Minimal ImpactModerateMajor Market Event